Albertsons Companies, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ACI research report →
Range $10 – $17
Price Chart
About the company
Albertsons Companies, Inc. , through its subsidiaries, operates in the food and drug retail industry in the United States. The company’s food and drug retail stores offer grocery products, general merchandise, health and beauty care products, pharmacy, vaccines, fuel, and other items and services.
- CEO
- Susan Morris
- IPO
- 2020
- Employees
- 275,000
- HQ
- Boise, ID, US
AI snapshot
Six angles, distilled from the data.
The stock is still in a corrective regime, trading below its 200-day average and well under the 52-week high. The longer-term setup is more range-bound than trending, with price action closer to the lower half of the yearly band than a sustained breakout.
Street sentiment is cautious: the consensus sits at Hold, with 7 Buys, 13 Holds, and 3 Sells. The average target is 13.17, above the last close but below the recent 17 high target, and the latest wave of changes skewed toward downgrades and lower near-term visibility.
The earnings profile is mixed but resilient enough to keep attention on execution. Albertsons has beaten 6 of the last 7 quarters, while the next quarter is estimated at $0.61 EPS after a $0.34 beat last time; shareholders should watch whether margins and grocery traffic offset softer top-line trends.
No discretionary insider buying or selling stands out. Recent filings are dominated by A-awards to the CEO, CFO, and directors, which look like compensation-related grants rather than a directional signal.
Profitability is thin but positive at the operating line, with a 1.89% operating margin and a 27.0% gross margin. Growth is soft, with revenue down 0.1% year over year and EPS TTM at -0.02, while free cash flow remains strong at $4.206 billion.
ACI screens like a defensive grocer with lower volatility than many consumer names, supported by a beta of 0.23. Valuation is modest at 5.49x earnings, which leaves it cheaper than the market but reflects slower growth and limited rerating momentum.
Similar companies
Peers in the same neighborhood.
- Market Cap
- $5.69B
- P/E
- -401.00
- Fwd P/E
- 6.95
- PEG
- 3.94
- P/S
- 0.07
- P/B
- 4.07
- EV/EBITDA
- 6.78
- Div Yield
- 5.49%
- Gross Margin
- 26.99%
- Op Margin
- 0.51%
- Net Margin
- -0.06%
- ROE
- -2.78%
- ROIC
- 1.23%
Latest fiscal year · YoY change
- Revenue
- $83.17B+3.5%
- Gross Profit
- $22.61B+1.6%
- Op Income
- $727.60M
- Net Income
- $217.40M-77.3%
- EPS
- $0.40-75.8%
- OCF Growth
- -11.7%
- FCF Growth
- -29.6%
- 52W High
- $18.83
- 52W Low
- $10.86
- 50D MA
- $12.68
- 200D MA
- $14.67
- Beta
- 0.23
- RSI (14)
- 38
- Avg Volume
- 8.11M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Albertsons said Q2 met expectations but confirmed a broad turnaround is underway, with management emphasizing faster cost cuts, sharper pricing, and a comprehensive business review due by Q4.· October 13, 2026
- Identical sales declined 0.8% in Q2, with adjusted EBITDA of $784 million and adjusted EPS of $0.36.
- E-commerce sales grew 11% and digital penetration reached 10.5%, while pharmacy script growth remained strong despite IRA and generic-mix headwinds.
- Management said the business is being simplified through ACI Edge, with cost savings now targeted to accelerate and more savings expected from buying, SG&A, shrink, and store execution.
- Albertsons declined to update full-year guidance, saying it will return in Q4 with a refreshed customer strategy, productivity program, portfolio actions, and capital allocation framework.
- The company reiterated strong cash generation and capital returns, including $1.2 billion of operating cash flow in the first half and about $400 million of share repurchases in the first half.
Q2 identical sales declined 0.8%. Adjusted EBITDA was $784 million and adjusted EPS was $0.36 per diluted share. Gross margin was 26.8%, down 17 basis points year over year excluding fuel and LIFO, while selling and administrative expense rate excluding fuel increased 38 basis points year over year. Interest expense rose to $125 million from $105 million last year. In the first half of 2026, operating cash flow was $1.2 billion, capital expenditures were about $900 million, free cash flow was more than $300 million, and net leverage ended at 2.4x. The company repurchased about $175 million of stock in Q2 and about $400 million in the first half, with $1.7 billion remaining under the refreshed $2 billion authorization. It also paid a $0.17 quarterly dividend and declared another $0.17 dividend. Management did not provide updated full-year or next-quarter guidance, saying it would come back with a comprehensive plan and multi-year outlook by the fourth quarter earnings call.
Susan Morris framed the quarter as evidence that Albertsons is not moving fast enough, even though there were early signs of improvement in cost takeout and in-store execution. She said the company is narrowing its focus to core customer-facing improvements, simpler operations, and faster execution, while doubling down on basics like price, promotions, freshness, and service. Her tone was candid and urgent, repeatedly stressing that the company must move faster and close the gap between potential and actual performance.
Cody Perdue focused on the gap between Albertsons’ cash-generating strength and its weaker sales and earnings trajectory. He cited Q2 gross margin of 26.8%, SG&A pressure from lower sales, interest expense of $125 million, and first-half operating cash flow of $1.2 billion with free cash flow above $300 million. He also highlighted balance-sheet flexibility, noting net leverage of 2.4x, about $400 million of buybacks in the first half, and $1.7 billion still available under the authorization, while explaining that management chose not to update guidance because a comprehensive review could alter investment timing, cost reduction, and portfolio decisions.
Analysts pressed on why the company announced a comprehensive review now, and management said it is an evolution of ACI Edge driven by slower-than-needed progress, more complexity in the business, and the need to go faster on fewer priorities. Questions also focused on cost savings, pricing, shrink, and the portfolio; management said there is still substantial room on cost out, especially in cost of goods, goods not for resale, and SG&A, and that underperforming assets will be reviewed but nothing specific is being disclosed yet. On guidance, the company said the second-quarter exit rate was unchanged, but it wanted time to finalize the pace, mix, and timing of investments and savings before giving a broader outlook.
The bull case from the call is that Albertsons still has strong local banners, robust pharmacy and e-commerce assets, and meaningful cash flow to fund a turnaround. Management sounded increasingly committed to aggressive simplification, cost reduction, and selective price investment, while saying early signs of improvement are already visible in buying, store execution, and digital growth.
The bear case is that same-store sales were still negative, traffic and units remain pressured, and management openly said results have not matched the quality of the assets. The company also acknowledged higher inflation, pricing pressure from lower-income consumers trading down, shrink issues tied to the cyclospora outbreak, and the possibility that the review could lead to portfolio exits, all of which add uncertainty before any new outlook is provided.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 67.0%
- Shares Outstanding
- 470.48M
- Float Shares
- 315.09M
of shares held by institutions
470 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Congressional trading
Senate and House stock disclosures for ACI, newest first.
| Member | Type | Traded | |
|---|---|---|---|
| Ro KhannaHouse · CA17 | Sell | Sep 22, 26 | Filing → |
| Ro KhannaHouse · CA17 | Sell | Sep 21, 26 | Filing → |
| Ro KhannaHouse · CA17 | Sell | Sep 23, 26 | Filing → |
| Ro KhannaHouse · CA17 | Sell | Sep 14, 26 | Filing → |
| Ro KhannaHouse · CA17 | Sell | Sep 22, 26 | Filing → |
| Ro KhannaHouse · CA17 | Sell | Sep 14, 26 | Filing → |
| Ro KhannaHouse · CA17 | Sell | Sep 23, 26 | Filing → |
| Ro KhannaHouse · CA17 | Sell | Sep 21, 26 | Filing → |
| Ro KhannaHouse · CA17 | Sell | Jul 23, 26 | Filing → |
| Ro KhannaHouse · CA17 | Buy | Apr 27, 26 | Filing → |
| Julia LetlowHouse · LA05 | Sell | Aug 26, 25 | Filing → |
| Julia LetlowHouse · LA05 | Buy | Jan 24, 25 | Filing → |
| Lisa C. McClainHouse · MI09 | Buy | Sep 11, 25 | Filing → |
| Lisa C. McClainHouse · MI09 | Sell | Jul 22, 25 | Filing → |
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Cerberus Capital Management, L.P. | 151.82M | 0 |
| Blackrock, Inc. | 41.98M | ▼ 1.07M |
| Vanguard Group Inc | 39.33M | ▲ 5.11M |
| Vanguard Portfolio Management LLC | 18.50M | ▲ 19.44K |
| Norges Bank | 17.09M | ▲ 17.09M |
| Dimensional Fund Advisors LP | 16.20M | ▲ 76.43K |
| Lsv Asset Management | 14.74M | ▲ 2.84M |
| Jpmorgan Chase & Co | 14.36M | ▲ 980.61K |
| Vanguard Capital Management LLC | 14.34M | ▼ 1.38M |
| Massachusetts Financial Services Co | 11.78M | ▼ 763.14K |
| State Street Corp | 11.33M | ▼ 537.77K |
| Southeastern Asset Management Inc | 8.64M | ▲ 1.22M |
Held by 553 ETFs
Biggest fund positions in ACI by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 6, 26 | TURNER BRIAN KEVIN | other | 146 |
| Nov 6, 26 | Boltz William P | other | 72 |
| Nov 6, 26 | MORRIS SUSAN | other | 4,581 |
| Nov 6, 26 | MORRIS SUSAN | other | 2,375 |
| Nov 6, 26 | MORRIS SUSAN | other | 1,184 |
| Nov 6, 26 | MORRIS SUSAN | other | 527 |
| Nov 6, 26 | Perdue Cody | other | 533 |
| Nov 6, 26 | Perdue Cody | other | 324 |
| Nov 6, 26 | Perdue Cody | other | 229 |
| Nov 6, 26 | Perdue Cody | other | 108 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our ACI coverage
Recent articles, reports, and earnings notes.

Albertsons Companies (ACI): Turnaround Upside, But Execution Risk
Albertsons is a turnaround story with defensible grocery assets, but weak earnings, heavy debt, and withdrawn guidance keep the stock in Hold territory. Cost savings, digital growth, and pharmacy strength support the recovery case.

Albertsons Companies, Inc. (ACI) gains on deep earnings analysis
Albertsons Companies, Inc. (ACI) gains after a modest earnings beat, but the deeper story is mixed. Adjusted EPS and revenue topped estimates, while identical sales, margins, and traffic stayed under pressure. We break down the operating trends, digital growth, pharmacy headwinds, and the company’s updated cost-savings plan.

Albertsons Companies, Inc. (ACI) gains on earnings beats
Albertsons Companies, Inc. (ACI) gains 2.2% after reporting earnings beats, as investors react positively to stronger-than-expected results and improved outlook signals.
Want a deeper read on ACI?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
Albertsons Companies® Announces General Counsel Transition
businesswire.com · Nov 18
ACI Worldwide Appoints Robert Leibrock as Interim Chief Executive Officer
businesswire.com · Nov 18
Albertsons Companies Is On Sale Even After Surging
seekingalpha.com · Nov 15
4 Top Dividend Stocks Yielding 4% or More to Buy Right Now for Passive Income
fool.com · Nov 15
Albertsons taps outsider Andrew Murray as CFO amid business review
reuters.com · Nov 10
Albertsons® Companies Names Andrew Murray Chief Financial Officer
businesswire.com · Nov 10
Kroger and Albertsons' CEOs Just Signaled the Walmart Price Gap Is Here to Stay. It Costs a Couple About $1,000 a Year.
247wallst.com · Nov 9
The Court Announces Award of $900 Million to the State of Washington From Albertsons Following Nine-Week Opioid Trial
businesswire.com · Nov 5
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.
AI analysis · Last refreshed November 20, 2026 · Live quote · Not investment advice